FDA warns about bolus heparin dosing
Baxter is suspending production of multi-dose vials of injectable heparin following a recent spike in adverse event reports, FDA says Feb. 11. Adverse events such as serious allergic reactions and hypotension seem to be associated with high bolus doses of the anticoagulant but not other routes of administration, the agency warns. FDA is inspecting Baxter's Cherry Hill, N.J., plant and plans to inspect the facility of the active ingredient manufacturer in China, as well as the finished dosage form manufacturing facility in New Jersey. The agency also is analyzing event reports and testing samples of Baxter's heparin product to identify the root cause of the incidents. No safety signal has been identified related to use of heparin manufactured by APP Pharmaceuticals, the other major U.S. supplier of injectable heparin. Baxter will continue to manufacture and distribute single-dose vials, and FDA is working with other manufacturers to identify alternate heparin sources in case Baxter's manufacturing suspension leads to a market shortage...
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.